Luvis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.67 M
as on 17-07-2024
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.51 M
as on 17-07-2024
- Satisfied Charges ₹ 6.00 M
as on 17-07-2024
- Revenue 24.82%
(FY 2022)
- Profit -32.20%
(FY 2022)
- Ebitda -51.39%
(FY 2022)
- Net Worth 3.26%
(FY 2022)
- Total Assets 12.14%
(FY 2022)
About Luvis Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.67 M.
The company currently has active open charges totaling ₹9.51 M. The company has closed loans amounting to ₹6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Veena Gupta, Rituparn Gupta, and Satish Gupta serve as directors at the Company.
- CIN/LLPIN
U24232CT2009PTC021036
- Company No.
021036
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Luvis Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veena Gupta  | Director | 04-Feb-2009 | Current |
| Rituparn Gupta | Director | 04-Feb-2009 | Current |
| Satish Gupta | Director | 12-Mar-2009 | Current |
Financial Performance of Luvis Pharmaceuticals.
Luvis Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 24.82% increase. The company also saw a substantial fall in profitability, with a 32.2% decrease in profit. The company's net worth moved up by a moderate rise of 3.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Luvis Pharmaceuticals?
In 2023, Luvis Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 30 Sep 2022 | ₹0.80 M | Open |
Uco Bank Creation Date: 26 Feb 2014 | ₹8.71 M | Open |
Bank Of Baroda Creation Date: 13 Jun 2011 | ₹4.00 M | Satisfied |
How Many Employees Work at Luvis Pharmaceuticals?
Unlock and access historical data on people associated with Luvis Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Luvis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Luvis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
